Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development

Cancer Journal

Volumn 6, Issue 4, 2000, Pages 192-212

  Kaubisch, A ^a   Schwartz, G K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alsterpaullone; Apoptosis; Bryostatin 1; Calphostin; Cancer; Cdk inhibitor; Cell cycle; CGP 41251; Cyclin dependent kinase; Flavopiridol; GF 109203X; Hypericin; ISIS 3521 CGP 64128A; Kenpaullone; LY333531; PKC inhibitor; Protein kinase C; Safingol; Staurosporine; UCN 01

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; 9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21; 9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21:12,17 DIMETHENODIBENZO[E,K]PYRROLO[3,4 H][1,4,13]OXADIAZACYCLOHEXADECINE 18,20(19H) DIONE; 9 BROMO 7,12 DIHYDROINDOLO[3,2 D 1]BENZAZEPIN 6(5H) ONE; 9 NITRO 7,12 DIHYDROINDOLO[3,2 D 1]BENZAZEPIN 6(5H) ONE; BISINDOLYLMALEIMIDE; BRYOSTATIN 1; CALPHOSTIN C; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; HYPERICIN; ISIS 3521; KW 2401; MITOMYCIN; N BENZOYLSTAUROSPORINE; NOCODAZOLE; NSC 664704; NSC 705701; PAULLONES; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RO 31 7453; RO 31 8220; RO 32 0432; SALFINGOL; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMAN; MICE; NEOPLASMS; PROTEIN KINASE C; RATS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033787348     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (246)

1. Cyclins and cell cycle checkpoints
2. Multiple molecular levels of cell cycle regulation
3. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
4. Cyclins, CDKs and cancer
5. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities
6. CDK inhibitors: Positive and negative regulators of G1-phase progression
7. Overexpression of cyclin D1 in rat flbroblasts causes abnormalities in growth control, cell cycle progression and gene expression
8. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells
9. Disorders in cell circuitry associated with multistage carcinogenesis: Exploitable targets for cancer prevention and therapy
10. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells
11. Apoptosis in cancer therapy: Crossing the threshold
12. Cell death in health and disease: The biology and regulation of apoptosis
13. Apoptosis meets signal transduction: Elimination of a BAD influence
14. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes
15. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
16. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
17. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
18. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
19. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells
20. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
21. Cell death: The significance of apoptosis
22. Induction of apoptosis: New targets for cancer chemotherapy
23. Defining apoptosis
24. Mechanisms of apoptosis: Integration of genetic, biochemical, and cellular indicators
25. An evolutionary perspective on apoptosis
26. Dysregulation of apoptosis in cancer
27. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
28. Protease activation during apoptosis: Death by a thousand cuts?
29. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
30. Cleavage of poly(-ADP-ribose) polymerase by a proteinase with properties like ICE
31. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
32. Degradation of lamin Bl precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei
33. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution
34. Apoptosis and carcinogenesis
35. Apoptosis: Its significance in cancer and cancer therapy
36. Implications of apoptotic cell death regulation in cancer therapy
37. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis
38. Apoptosis and cancer drug targeting
39. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents
40. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents
41. Bcl-2 and the regulation of programmed cell death
42. Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation
43. Bcl-xL overexpression inhibits Taxol-induced Yama protease activity and apoptosis
44. Involvement of the bcl-2 gene in human follicular lymphoma
45. Protein kinase C targeting in antineoplastic treatment strategies
46. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway
47. Programmed cell death induced by ceramide
48. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells
49. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis
50. Protein kinase C involvement in apoptosis
51. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways
52. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes
53. Modulation of protein kinase C-epsilon by phorbol esters in the monoblastoid U937 cell
54. Analyses of protein kinase C isoform expression in a colorectal cancer liver metastasis model
55. Expression and characterization of protein kinase C-delta
56. Predominant expression of nPKC eta, a Ca(2 +)-independent isoform of protein kinase C in epithelial tissues, in association with epithelial differentiation
57. A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin
58. Effect of phorbol esters on protein kinase C-zeta
59. Expression, purification, and characterization of protein kinase C-epsilon
60. Protein kinase C heterogeneity in GH4Cl rat pituitary cells: Characterization of a Ca2(+)-independent phorbol ester receptor
61. Sequence and expression of human protein kinase C-epsilon
62. Protein kinase C zeta subspecies from rat brain: Its structure, expression, and properties
63. Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart
64. Protein kinase C group B members PKC-delta, -epsilon, -zeta and PKC-L(eta): Comparison of properties of recombinant proteins in vitro and in vivo
65. The role of protein kinase C in cell surface signal transduction and tumour promotion
66. The protein kinase C family: Heterogeneity and its implications
67. Studies and perspectives of protein kinase C
68. The distinct biological potential of PKC isotypes
69. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis
70. Involvement of protein kinase C-epsilon in glucocorticoid-induced apoptosis in thymocytes
71. Changes in protein kinase C isoenzyme expression associated with apoptosis in U937 myelomonocytic cells
72. Protein kinase C as the receptor for the phorbol ester tumor promoters: Sixth Rhoads Memorial Award Lecture
73. Protein kinase C: Structure, function, and regulation
74. Protein kinase C and lipid signaling for sustained cellular responses
75. Regulation of protein kinase C and role in cancer biology
76. Potential for protein kinase C inhibitors in cancer therapy
77. Protein kinase C modulation
78. PKCs: Transducers of critical signals in cancer cells
79. Potent and specific inhibitors of protein kinase C of microbial origin
80. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60
81. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner
82. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
83. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
84. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paditaxel-treated human gastric and breast cancer cells
85. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
86. Protein kinase C inhibitors as inducers of apoptosis for cancer therapy
87. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
88. Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development
89. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
90. Preclinical and clinical development of cyclin-dependent kinase modulators
91. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets
92. Protein kinase C: A novel target for inhibiting gastric cancer cell invasion
93. Inhibition of protein kinase C by safingol is associated with chemosensitization of multidrug resistant MCF-7 cells
94. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents
95. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers
96. Combined effect of the chemopotentiator SPC-100270, a PKC inhibitor, and doxorubicin or cisplatin (Cis) on murine isografts and human tumor xenografts
97. Effect of the protein kinase C (PKC) inhibitor SPC-100270 on drug accumulation and cytotoxicity in drug resistant and sensitive tumor cells in vitro
98. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells
99. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor salingol alone and in combination with doxorubicin
100. UCN-01 and UCN-02, new selective inhibitors of protein kinase C: II. Purification, physico-chemical properties, structural determination and biological activities
101. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
102. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
103. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
104. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53
105. UCN-01, a selective inhibitor of protein kinase C from Streptomyces
106. The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma
107. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines
108. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor
109. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells
110. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
111. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
112. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
113. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
114. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
115. The Chkl protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
116. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cyde distribution of human epidermoid carcinoma A431 cells
117. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
118. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/CiplAVAFl/Sdil in p53-mutated human epidermoid carcinoma A431 cells
119. The retinoblastoma gene product is a negative modulator of the apoptotic pathway
120. The role of E2F in the mammalian cell cycle
121. Cellular targets for activation by the E2Fl transcription factor include DNA synthesis- and G1/S-regulatory genes
122. Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members
123. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines
124. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate
125. Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle
126. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alphalacid glycoprotein
127. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
128. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
129. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
130. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter
131. The protein kinase C (PKC) inhibitor staurosporine derivative CGP 41251 enhances the in vitro cytotoxicity of doxorubicin (DOX) against multidrug resistant (MDR) routine fibrosarcoma, murine colon carcinoma, and human breast carcinoma cells
132. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation
133. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole
134. Treatment of human glioblastoma cells with the staurosponne derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity
135. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
136. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
137. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C
138. (S)-13-[(dimethylamin o)methyl]-10, 11, 14, 15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta
139. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
140. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531
141. Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy
142. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
143. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
144. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
145. Apoptosis induced by protein kinase C inhibition in a neuroblastoma cell line
146. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells
147. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase
148. The protein kinase C inhibitor Ro 32-0432 significantly enhances mitomycin-C induced apoptosis
149. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60
150. Demonstration of subnanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain
151. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
152. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C
153. Ubiquitination of protein kinase C-alpha and degradation by the proteasome
154. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2
155. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937)
156. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
157. Induction of differentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1
158. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh
159. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro
160. Successful treatment of murine melanoma with bryostatin 1
161. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
162. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells
163. Activation of human T lymphocytes by bryostatin
164. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines
165. Effects of activators of protein kinase C
166. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents
167. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: Association with enhanced fragmentation of mature DNA
168. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
169. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee
170. A phase 1 trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
171. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: A 31P magnetic resonance spectroscopic study
172. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
173. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
174. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
175. Phase 1 trial of prolonged infusion bryostatin-1 in patients with advanced cancer
176. Phase I trial of bryostatin-1 in childhood solid tumors: A Pediatric Oncology Group (POG) study
177. Treatment of patients with metastatic melanoma with bryostatin-1: A phase II study
178. Phase I trial of weekly sequential bryostatin-1 (Bryo), cisplatin, and paclitaxel in patients with advanced solid tumors
179. Phase 1 study of bryostatin-1 and cisplatin in patients with advanced cancer
180. Phase I study of bryostatin-1 and cisplatin (CDDP)
181. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies
182. An antiinflammatory cum immodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure, and total synthesis
183. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
184. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
185. Alteration of the phosphorylation state of p34 cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased Hi kinase activity
186. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
187. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
188. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck
189. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis
190. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers
191. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
192. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
193. Loss of p21Wafl/Cipl sensitizes tumors to radiation by an apoptosis-independent mechanism
194. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
195. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer
196. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
197. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
198. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
199. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
200. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
201. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment
202. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells
203. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
204. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
205. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat
206. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line
207. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
208. Phase I clinical and pharmacokinetic trial of HMR 1275
209. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
210. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer
211. The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
212. Phase I trial of sequential paclitaxel and the cyclin-dependent kinase inhibitor flavopiridol
213. Design, synthesis and investigation of mechanisms of action of novel protein kinase C inhibirors: Perylenequinonoid pigments
214. Calphostin C (UCN-1028), a novel and specific inhibitor of protein kinase C
215. Calphostin (UCN 1028) and calphostin related compounds, a new class of specific and potent inhibitors of protein kinase C
216. Inhibition of protein kinase C by calphostin C is light-dependent
217. Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor
218. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C
219. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C
220. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells
221. Hypericin: A potential antiglioma therapy
222. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C
223. Light-dependent inhibition of protein kinase C and superoxide generation of neutrophils by hypericin, an antiretroviral agent
224. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression
225. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha
226. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice
227. Phase I evaluation of IS1S 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
228. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
229. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer
230. Efficacy, toxicity, and pharmacology of an antisense oligonucleotide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continuous intravenous infusion in patients with recurrent high grade astrocytomas (HGA)
231. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression
232. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
233. Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
234. Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death
235. Multimodality therapy: Radiation and continuous concomitant cis-platinum and PKC inhibition in a cervtcal carcinoma model
236. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
237. UCN-01 and UCN-02, new selective inhibitors of protein kinase C: I. Screening, producing organism and fermentation
238. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C
239. Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction
240. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase
241. The change in research for the therapy of tumors
242. Antitumoral activity of flavone L86-8275
243. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs